文献速递免疫规划

单剂非洲马瘟病毒VP2疫苗在小鼠模型中提供完全临床保护

A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
PubMed 文献 · Vaccine · 2018-10-08

非洲马瘟是马属动物的严重虫媒病毒病,现有减毒活疫苗存在生物安全担忧。本研究用表达AHSV-VP2的MVA载体疫苗或杆状病毒亚单位疫苗接种干扰素α受体敲除小鼠,单剂或标准两剂方案后以AHSV攻毒,比较临床反应、致死率和病毒血症。结果显示单剂接种任一VP2疫苗即实现完全临床保护。

要点

  • 单剂MVA-VP2或杆状病毒VP2疫苗在小鼠中实现完全临床保护。
  • 研究比较了单剂与标准两剂方案,攻毒后评估临床反应、致死和病毒血症。
  • AHSV免疫具血清型特异性,地方性流行区疫苗需覆盖所有血清型。

核心结论

  • 单剂接种MVA-VP2或杆状病毒表达的VP2亚单位疫苗即可在小鼠模型中实现完全临床保护。

研究设计与样本

  • 研究使用干扰素α受体敲除小鼠,分组接种MVA-VP2或杆状病毒表达的VP2疫苗,采用单剂或标准两剂方案,随后以AHSV攻毒。

主要发现

  • 所有四个疫苗接种组在攻毒后均实现完全临床保护。
  • 研究比较了各组间的临床反应、致死率和病毒血症。

临床怎么用

  • 提示单剂VP2疫苗方案可能简化多价疫苗的接种程序,但结论基于小鼠模型,尚需在马匹中验证。

局限性

  • 研究仅在小鼠模型中进行,尚未在马匹中验证单剂保护效果。
  • 未报告单剂与两剂方案在保护效力上的具体比较数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

African horse sickness is a severe, often fatal, arboviral disease of equids. The control of African horse sickness virus (AHSV) in endemic countries is based currently on the use of live attenuated vaccines despite some biosafety concerns derived from its biological properties. Thus, experimental vaccination platforms have been developed over the years in order to avoid the biosafety concerns associated with the use of attenuated vaccines. Various studies showed that baculovirus-expressed AHSV-VP2 or modified Vaccinia Ankara virus expressing AHSV-VP2 (MVA-VP2) induced virus neutralising antibodies and protective immunity in small animals and horses. AHSV is an antigenically diverse pathogen and immunity against AHS is serotype-specific. Therefore, AHS vaccines for use in endemic countries need to induce an immune response capable of protecting against all existing serotypes. For this reason, current live attenuated vaccines are administered as polyvalent preparations comprising combinations of AHSV attenuated strains of different serotypes. Previous studies have shown that it is possible to induce cross-reactive virus neutralising antibodies against different serotypes of AHSV by using polyvalent vaccines comprising combinations of either different serotype-specific VP2 proteins, or MVA-VP2 viruses. However, these strategies could be difficult to implement if induction of protective immunity is highly dependent on using a two-dose vaccination regime for each serotype the vaccine intends to protect against. In our study, we have tested the protective capacity of MVA-VP2 and baculovirus-expressed VP2 vaccines when a single dose was used. Groups of interferon alpha receptor knock-out mice were inoculated with either MVA-VP2 or baculovirus-expressed VP2 vaccines using one dose or the standard two-dose vaccination regime. After vaccination, all four vaccinated groups were challenged with AHSV and clinical responses, lethality and viraemia compared between the groups. Our results show that complete clinical protection was achieved after a single vaccination with either MVA-VP2 or baculovirus sub-unit VP2 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Aksular M, Calvo-Pinilla E, Marín-López A, et al. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model. Vaccine. 2018. PMID: 30309744. doi:10.1016/j.vaccine.2018.09.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。